News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Elvina Almuradova: Using ICis as a first-line treatment may pose a risk of toxicity in unresectable ESCC
Elvina Almuradova/X
Sep 29, 2024, 16:20

Elvina Almuradova: Using ICis as a first-line treatment may pose a risk of toxicity in unresectable ESCC

Elvina Almuradova, Associate Professor of Oncology at Medicana Sağlık Grubu, shared a post on LinkedIn:

“The FDA has expressed concern that in patients with metastatic or unresectable esophageal squamous cell carcinoma, using immune checkpoint inhibitors as a first-line treatment may pose a risk of toxicity without offering a clear benefit for those with low PD-L1 expression (PD-L1 <1).”

Elvina Almuradova: Using ICis as a first-line treatment may pose a risk of toxicity in unresectable ESCC

Read further.
Source: Elvina Almuradova/LinkedIn

cancer Elvina Almuradova ESCC esophageal squamous cell carcinoma FDA Medicana Sağlık Grubu OncoDaily Oncology
Special Coverage
Insight
Nov 20, 2024, 20:44
Baris Turkbey: Excited to announce NCI Molecular Imaging members presenting their research at RSNA2024
Blog
Nov 20, 2024, 20:38
Franklin Iheanacho: Changing treatment patterns for hepatocellular carcinoma
Insight
Nov 20, 2024, 20:27
HIPEC improves overall survival in recurrent epithelial ovarian cancer
Blog
Nov 20, 2024, 19:12
Medicaid Cancer Foundation at 1Ummah Annual Convention
Insight
Nov 20, 2024, 19:12
Sahar Mansour: Advancing Breast Microcalcification Detection with AI
Blog
Nov 20, 2024, 19:12
Reflecting on Progress and Partnerships in Lung Cancer Care – Sarah Cannon Research Institute
Blog
Nov 20, 2024, 19:12
Virtual tumor board on the management of a patient with Metastatic Squamous NSCLC - IASLC
Insight
Nov 20, 2024, 19:12
Nareg Varjabedian: Antidiabetic Drugs and Cancer Prevention
Insight
Nov 20, 2024, 19:12
Paolo Ciracì: Late-line options for patients with metastatic colorectal cancer
Insight
Nov 20, 2024, 19:12
Physicians’ perspectives on cancer-related fatigue management: A cross-sectional survey study in Germany - MASCC
Insight
Nov 20, 2024, 19:12
Ajay Major: Golcadomide and R-CHOP as first line for LBCL by Arnaud Amzallag et al.
Blog
Nov 20, 2024, 19:12
Rahul Gosain: Role of diet and exercise in cancer with Neil Iyengar